Tumour Necrosis Factor-alpha Expression in Tumour Islets Confers a Survival Advantage in Non-small Cell Lung Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Jun 25

PMID 20573209

Citations 14

Authors

Chandra M Ohri

Aarti Shikotra

Ruth H Green

David A Waller

Peter Bradding

Affiliations

Soon will be listed here.

Abstract

Background: The role of TNFalpha in cancer is complex with both pro-tumourigenic and anti-tumourigenic roles proposed. We hypothesised that anatomical microlocalisation is critical for its function.

Methods: This study used immunohistochemistry to investigate the expression of TNFalpha in the tumour islets and stroma with respect to survival in 133 patients with surgically resected NSCLC.

Results: TNFalpha expression was increased in the tumour islets of patients with above median survival (AMS) compared to those with below median survival (BMS)(p = 0.006), but similar in the stroma of both groups. Increasing tumour islet TNFalpha density was a favorable independent prognostic indicator (p = 0.048) while stromal TNFalpha density was an independent predictor of reduced survival (p = 0.007). Patients with high TNFalpha expression (upper tertile) had a significantly higher 5-year survival compared to patients in the lower tertile (43% versus 22%, p = 0.01). In patients with AMS, 100% of TNFalpha+ cells were macrophages and mast cells, compared to only 28% in the islets and 50% in the stroma of BMS patients (p < 0.001).

Conclusions: The expression of TNFalpha in the tumour islets of patients with NSCLC is associated with improved survival suggesting a role in the host anti-tumour immunological response. The expression of TNFalpha by macrophages and mast cells is critical for this relationship.

Citing Articles

Controversial role of mast cells in NSCLC tumor progression and angiogenesis.

Longo V, Catino A, Montrone M, Galetta D, Ribatti D Thorac Cancer. 2022; 13(21):2929-2934.

PMID: 36196487 PMC: 9626321. DOI: 10.1111/1759-7714.14654.

Molecular Mechanism of Antioxidant and Anti-Inflammatory Effects of Omega-3 Fatty Acids in Perilla Seed Oil and Rosmarinic Acid Rich Fraction Extracted from Perilla Seed Meal on TNF-α Induced A549 Lung Adenocarcinoma Cells.

Tantipaiboonwong P, Chaiwangyen W, Suttajit M, Kangwan N, Kaowinn S, Khanaree C Molecules. 2021; 26(22).

PMID: 34833849 PMC: 8622939. DOI: 10.3390/molecules26226757.

Myeloid Cells in Glioblastoma Microenvironment.

De Leo A, Ugolini A, Veglia F Cells. 2020; 10(1).

PMID: 33374253 PMC: 7824606. DOI: 10.3390/cells10010018.

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk.

Sarode P, Schaefer M, Grimminger F, Seeger W, Savai R Front Oncol. 2020; 10:324.

PMID: 32219066 PMC: 7078651. DOI: 10.3389/fonc.2020.00324.

2019 Expert opinion on biological treatment use in inflammatory bowel disease management.

Toruner M, Akpinar H, Akyuz F, Dagli U, Over Hamzaoglu H, Tezel A Turk J Gastroenterol. 2020; 30(Suppl 4):S913-S946.

PMID: 32207688 PMC: 7372973. DOI: 10.5152/tjg.2019.061119.

References

Chen G, Goeddel D . TNF-R1 signaling: a beautiful pathway. Science. 2002; 296(5573):1634-5. DOI: 10.1126/science.1071924. View

Szlosarek P, Charles K, Balkwill F . Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006; 42(6):745-50. DOI: 10.1016/j.ejca.2006.01.012. View

Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M . Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer. 2000; 83(4):480-6. PMC: 2374649. DOI: 10.1054/bjoc.2000.1345. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Mountain C . Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-7. DOI: 10.1378/chest.111.6.1710. View

Brown E, Charles K, Hoare S, Rye R, Jodrell D, Aird R . A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008; 19(7):1340-1346. DOI: 10.1093/annonc/mdn054. View

OByrne K, Dalgleish A . Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001; 85(4):473-83. PMC: 2364095. DOI: 10.1054/bjoc.2001.1943. View

Locksley R, Killeen N, Lenardo M . The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001; 104(4):487-501. DOI: 10.1016/s0092-8674(01)00237-9. View

Lees C, Ironside J, Wallace W, Satsangi J . Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med. 2008; 359(3):320-1. DOI: 10.1056/NEJMc0800250. View

10.

Dalgleish A, OByrne K . Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006; 130:1-38. View

11.

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

12.

Stone J, Holbrook J, Marriott M, Tibbs A, Sejismundo L, Min Y . Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54(5):1608-18. DOI: 10.1002/art.21869. View

13.

Lejeune F, Lienard D, Matter M, Ruegg C . Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006; 6:6. View

14.

Balkwill F . Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002; 13(2):135-41. DOI: 10.1016/s1359-6101(01)00020-x. View

15.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

16.

Ohri C, Shikotra A, Green R, Waller D, Bradding P . Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009; 33(1):118-26. DOI: 10.1183/09031936.00065708. View

17.

Bazzoni F, Beutler B . The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334(26):1717-25. DOI: 10.1056/NEJM199606273342607. View

18.

Mastroeni P, Villarreal-Ramos B, Hormaeche C . Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. Microb Pathog. 1993; 14(6):473-80. DOI: 10.1006/mpat.1993.1046. View

19.

Welsh T, Green R, Richardson D, Waller D, OByrne K, Bradding P . Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. DOI: 10.1200/JCO.2005.01.4910. View

20.

Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized,.... Arthritis Rheum. 2004; 50(5):1400-11. DOI: 10.1002/art.20217. View